Pfizer has received EMA approval for the pneumococcal conjugate vaccine Apexxnar. The drug is intended for active immunization to prevent invasive diseases and pneumonia caused by Streptococcuspneumoniae in people 18 years and older. The approval is valid in all 27 EU countries as well as Iceland, Liechtenstein and Norway.